Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up

被引：4
|
作者：
Annunziata, M. L. [1 ]
Papparella, L. G. [1 ]
Sansoni, I. [2 ]
Balestrieri, P. [1 ]
Cicala, M. [1 ]
机构：
[1] Campus Bio Med, Gastroenterol, Rome, Italy
[2] Campus Bio Med, Radiol, Rome, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60522-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P402
引用
收藏
页码：S233 / S233
页数：1
相关论文
共 50 条
  • [31] Infliximab for inflammatory arthritis in clinical practice:: Drug survival after three years of follow-up
    Hernandez, M. V.
    Gomez-Puerta, J. A.
    Vazquez, I.
    Graell, E.
    Rodriguez-Cros, J.
    Goncalves, M. J.
    Saura, C.
    Garcia, S.
    Canete, J. D.
    Carmona, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 321 - 321
  • [32] LOCAL INJECTION OF INFLIXIMAB AFTER SURGERY IN SEVERE FISTULATING PERIANAL CROHN'S DISEASE: LONG-TERM FOLLOW-UP
    Alessandroni, L.
    Kohn, A.
    Cosintino, R.
    Marrollo, M.
    Papi, C.
    Monterubbianesi, R.
    Tersigni, R.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S184 - S184
  • [33] Clinical Remission After Stopping Infliximab in Crohn's Disease: Is All That Glitters True Gold? Reply
    Louis, Edouard
    Mary, Jean-Yves
    Colombel, Jean-Frederic
    GASTROENTEROLOGY, 2012, 142 (05) : E18 - E18
  • [34] Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort
    de Ridder, Lissy
    Rings, Edmond H. H. M.
    Damen, Gerard M.
    Kneepkens, C. M. Frank
    Schweizer, Joachim J.
    Kokke, Freddy T. M.
    Benninga, Marc A.
    Norbruis, Obbe F.
    Hoekstra, J. Hans
    Gijsbers, Carolien F. M.
    Escher, Johanna C.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (03) : 353 - 358
  • [35] Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
    Lee, Yun Seok
    Baek, Sang Hun
    Kim, Mi Jin
    Lee, Yoo Min
    Lee, Yoon
    Choe, Yon Ho
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2012, 15 (04) : 243 - 249
  • [36] Safety of Infliximab and Other Crohn's Disease Therapies: TREAT™ Registry Data With 27, 762 Patient-Years of Follow-up
    Lichtenstein, Gary
    Cohen, Russell D.
    Feagan, Brian G.
    Salzberg, Bruce
    Turner, Michelle
    Mink, David
    Langholff, Wayne K.
    Broussard, Delma L.
    Diamond, Robert
    Sandborn, William J.
    GASTROENTEROLOGY, 2010, 138 (05) : S475 - S475
  • [37] Double balloon enteroscopy in paediatric Crohn's disease and 10 years follow-up
    Oba, J.
    Carlos, A.
    Azevedo, M.
    Milani, L.
    Freitas, N.
    Toma, R.
    Bibas, M.
    Damiao, A.
    Safatle-Ribeiro, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S253 - S253
  • [38] Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission?
    Lamartina, Livia
    Handkiewicz-Junak, Daria
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 182 (05) : D1 - D16
  • [39] Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1-year follow-up of gain trial
    Panaccione, Remo
    Sandbom, William J.
    D'Haens, Geert
    Enns, Robert A.
    Wolf, Douglas C.
    Lomax, Kathleen G.
    Pollack, Paul F.
    GASTROENTEROLOGY, 2008, 134 (04) : A133 - A134
  • [40] Successful treatment of neuro-Behcet's disease with infliximab: four years follow-up
    Kaur, Manjinder
    Nia, Emily S.
    Millius, Rebecca A.
    Sudano, Dominick G.
    Lisse, Jeffrey R.
    RHEUMATOLOGY REPORTS, 2015, 7 (01) : 14 - 16
12345